Casodex

DRUG8 trials

Sponsors

Radiation Therapy Oncology Group, Dana-Farber Cancer Institute, Schiffler Cancer Center, M.D. Anderson Cancer Center, AstraZeneca

Conditions

Adenocarcinoma of the ProstateGynaecomastiaProstate Cancer

Phase 1

Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer

CompletedNCT00631527

M.D. Anderson Cancer CenterProstate Cancer

Start: 2008-02-29Updated: 2015-01-29

Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate

CompletedNCT02064036

University of California, DavisAdenocarcinoma of the Prostate

Start: 2013-06-06End: 2021-10-29Updated: 2022-10-18

Phase 2

Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment

CompletedNCT00165399

Dana-Farber Cancer InstituteAdenocarcinoma of the Prostate, Prostate Cancer

Start: 2004-03-31End: 2005-12-31Updated: 2018-06-25

Casodex - Nolvadex Combination

CompletedNCT00637871

AstraZenecaGynaecomastia, Prostate Cancer

Start: 2002-11-30End: 2005-08-31Updated: 2011-01-24

Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer

CompletedNCT01250717

Beth Israel Deaconess Medical CenterProstate Cancer

Start: 2001-01-31End: 2011-05-31Updated: 2014-02-04

Degarelix Neo-Adjuvant Radical Prostatectomy Trial

CompletedNCT01674270

University Health Network, TorontoProstate Cancer

Start: 2012-08-31End: 2015-11-30Updated: 2015-12-22

Phase 3

Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

CompletedNCT00005044

Radiation Therapy Oncology GroupProstate Cancer

Start: 2000-02-29End: 2022-05-20Updated: 2022-06-15

Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial

TerminatedNCT00243646

Schiffler Cancer CenterProstate Cancer

Start: 2004-08-31End: 2009-07-31Updated: 2016-04-14

Related Papers

Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer

NEJM Evidence2023-06-29101 citations

Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial.

2010-10-2129 citations